uniQure (QURE) reported second-quarter 2026 revenue of $5.8 million, up from $5.3 million a year earlier. The company posted a net loss of $81.1 million, or $1.22 basic and diluted loss per ordinary share.
The gene therapy company said U.S. and U.K. regulatory submissions for AMT-130 in Huntington’s disease remain planned for the third quarter of 2026. uniQure also reported $810.3 million in cash, cash equivalents and current investment securities as of June 30, 2026, and said its resources are expected to fund projected operating expenses into 2030.
- Revenue was $5.8 million for the quarter ended June 30, 2026, compared with $5.3 million a year earlier.
- Net loss was $81.1 million, compared with a $37.7 million net loss in the same period of 2025.
- AMT-130 BLA submission remains expected in the third quarter of 2026, with four-year data planned for September 2026.
- AMT-260 preliminary data showed three of six low-dose cohort patients had 79% to 100% reductions in disabling seizures during months four through six.
- Cash position totaled $810.3 million after a $259 million follow-on offering completed in June 2026.
$QURE Insider Trading Activity
$QURE insiders have traded $QURE stock on the open market 44 times in the past 6 months. Of those trades, 0 have been purchases and 44 have been sales.
Here’s a breakdown of recent trading of $QURE stock by insiders over the last 6 months:
- MATTHEW C KAPUSTA (CEO, Managing Director) has made 0 purchases and 16 sales selling 323,990 shares for an estimated $12,864,928.
- JACK KAYE has made 0 purchases and 5 sales selling 31,100 shares for an estimated $1,341,745.
- MADHAVAN BALACHANDRAN has made 0 purchases and 5 sales selling 23,678 shares for an estimated $858,915.
- KYLIE O'KEEFE (Chief Customer & Strat Officer) sold 15,936 shares for an estimated $431,228
- CHRISTIAN KLEMT (Chief Financial Officer) has made 0 purchases and 3 sales selling 30,749 shares for an estimated $381,751.
- ROBERT GUT has made 0 purchases and 4 sales selling 10,278 shares for an estimated $270,485.
- JEANNETTE POTTS (Chief Legal Officer) has made 0 purchases and 3 sales selling 17,227 shares for an estimated $261,171.
- WALID ABI-SAAB (Chief Medical Officer) has made 0 purchases and 3 sales selling 3,902 shares for an estimated $91,034.
- LEONARD E POST sold 1,993 shares for an estimated $53,930
- DAVID D. MEEK sold 1,993 shares for an estimated $53,930
- JEREMY P. SPRINGHORN sold 1,993 shares for an estimated $53,930
- RACHELLE SUZANNE JACQUES sold 1,993 shares for an estimated $53,930
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$QURE Hedge Fund Activity
We have seen 110 institutional investors add shares of $QURE stock to their portfolio, and 104 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC removed 4,497,128 shares (-72.1%) from their portfolio in Q1 2026, for an estimated $73,528,042
- ABERDEEN GROUP PLC added 1,627,746 shares (+44.2%) to their portfolio in Q1 2026, for an estimated $26,613,647
- ORBIMED ADVISORS LLC added 1,398,749 shares (+189.7%) to their portfolio in Q1 2026, for an estimated $22,869,546
- TWO SEAS CAPITAL LP added 1,300,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $21,255,000
- TWO SIGMA INVESTMENTS, LP added 1,224,587 shares (+84.4%) to their portfolio in Q1 2026, for an estimated $20,021,997
- SUVRETTA CAPITAL MANAGEMENT, LLC removed 1,216,734 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $19,893,600
- RTW INVESTMENTS, LP removed 1,125,106 shares (-30.3%) from their portfolio in Q1 2026, for an estimated $18,395,483
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
